Shuttle Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Shuttle Pharmaceuticals, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT06359379
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, New Jersey, United States
News
No news found